Drais Pharmaceuticals Inc., President and Chief Executive Officer
Dr. Tempel is President, Chief Executive Officer and co-founder of Drais Pharmaceuticals Inc. Drais is a venture-capital supported clinical drug development company, based in Bridgewater, New Jersey.
The company specializes in early phase clinical development and seeks to establish close partnerships with larger pharmaceutical companies in order to build its pipeline and accelerate promising candidates to proof of concept. Prior to founding Drais, Dr. Tempel was co-founder and Chief Operating Officer of AkaRx, Inc., also a venture-backed development company. AkaRx was spun out of the merger of Yamanouchi and Fujisawa in 2005 with a focus in hematology/oncology. AkaRx was acquired by Eisai Inc. in January of 2010. Prior to the founding of AkaRx Inc., Dr. Tempel was Vice President of Project Management at Yamanouchi, responsible for oversight of all clinical development programs for the company in the US and EU including the now-marketed products, Vesicare™ and Vaprisol™. Prior to joining Yamanouchi in 1998, Dr. Tempel held various positions in Research and Development at Bristol-Myers Squibb and Johnson & Johnson, Inc. Dr. Tempel received her B.S. in Psychology and Mathematics from Hunter College/CUNY, a Ph.D. in Neuroscience from CUNY/Mount Sinai School of Medicine and an MBA in Finance from Farleigh Dickinson University.